Sotevtamab
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb) . Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research[1][2][3].
Product Specifications
CAS Number
[2411526-47-9]
Product Name Alternative
16B5; AB-16B5
UNSPSC
12352203
Target
Apoptosis
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sotevtamab.html
Purity
99.67
Solubility
10 mM in DMSO
Smiles
[Sotevtamab]
Molecular Weight
(146.2 kDa)
References & Citations
[1]Gilles Tremblay, et al. Abstract 1467: AB-16B5, a therapeutic monoclonal antibody against human clusterin that blocks the epithelial-to-mesenchymal transition. Cancer Res 15 April 2010; 70 (8_Supplement) : 1467. |[2]Cristiano Ferrario, et al. Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies. Cancer Res 1 July 2017; 77 (13_Supplement) : CT098. |[3]Gilles B. et al. Pre-clinical evaluation of AB-16B5, a monoclonal antibody specific for tumor-associated sCLU, demonstrates therapeutic potential as an inhibitor of EMT in prostate, pancreatic and lung cancer. Cancer Res 15 April 2011; 71 (8_Supplement) : LB–33.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
